# ArriVent BioPharma, Inc. (AVBP) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from ArriVent BioPharma, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AVBP/mda/fy2025/): filed 2026-03-05; accession 0001104659-26-024127 (https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/avbp-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/AVBP/mda/fy2024/): filed 2025-03-03; accession 0001558370-25-001999 (https://www.sec.gov/Archives/edgar/data/1868279/000155837025001999/avbp-20241231x10k.htm)
- [FY 2023 MD&A](/company/AVBP/mda/fy2023/): filed 2024-03-28; accession 0001558370-24-004280 (https://www.sec.gov/Archives/edgar/data/1868279/000155837024004280/tmb-20231231x10k.htm)

Back to /company/AVBP/